BIOPIX-T, which was founded in 2019 and has its headquarters in Heraklion, Crete, aims to revolutionize molecular diagnostics at the Point-Of-Care and Home-Testing environments. Their flagship product is a mobile COVID-19 detection device, called Iris, which can identify the presence of the virus in a sample in just half an hour. The device, which functions just like a mini laboratory, is expected to be launch on the market in 2021. Created using 3D printing technology, Iris is backed by €2.4 million of EU funding.
Articles about BIOPIX-T:
- January 25, 2021 10 promising Greece-based startups to watch in 2021